Literature DB >> 15189271

Incidence and risk factors for acute renal failure in patients with hepatocellular carcinoma undergoing transarterial chemoembolization: a prospective study.

Teh-Ia Huo1, Jaw-Ching Wu, Pui-Ching Lee, Full-Young Chang, Shou-Dong Lee.   

Abstract

BACKGROUND: Transarterial chemoembolization (TACE) is effective for hepatocellular carcinoma (HCC). Considerable amounts of radiocontrast agent are used for TACE and may induce renal dysfunction.
METHOD: This study prospectively investigated the incidence and risk factors of acute renal failure (ARF), defined as an increase of serum creatinine level >1.5 mg/dl after TACE.
RESULTS: ARF developed in 12 (8.6%) of 140 patients after TACE. Univariate analysis showed that number of treatment sessions (2.3 +/- 1.4 vs 1.3 +/- 1.6, P=0.013), Child-Pugh class B (50% vs 21%, P=0.035) and the occurrence of severe postembolization syndrome (75% vs 30%, P=0.020) were significantly associated with the development of ARF. Multivariate logistic regression analysis disclosed that the proportional increased risk of ARF was 65% for each additional TACE therapy (odds ratio [OR]: 1.65, 95% confidence interval [CI]: 1.13-2.41, P=0.010). Other independent risk factors were Child-Pugh class B (OR: 12.82, 95% CI: 2.44-67.29, P=0.003) and severe postembolization syndrome (OR: 6.64, 95% CI: 1.60-27.49, P=0.009). Four (33%) of the patients with ARF developed irreversible renal function impairment, and diabetes mellitus was the only associated factor (P=0.067) in this group.
CONCLUSIONS: ARF after TACE is closely associated with number of treatment sessions, severity of cirrhosis and development of severe postembolization syndrome. Effective preventive measures should be undertaken especially in high-risk patients. Copyright 2004 Blackwell Munksgaard

Entities:  

Mesh:

Year:  2004        PMID: 15189271     DOI: 10.1111/j.1478-3231.2004.00911.x

Source DB:  PubMed          Journal:  Liver Int        ISSN: 1478-3223            Impact factor:   5.828


  19 in total

1.  Tumour Lysis Syndrome: a Rare Complication of Trans-Arterial Chemo-Embolisation with Doxorubicin Beads for Hepatocellular Carcinoma.

Authors:  Diana Katiman; Jeeta Manikam; Khean-Lee Goh; Basri Johan Abdullah; Sanjiv Mahadeva
Journal:  J Gastrointest Cancer       Date:  2012-09

2.  Complications of hepatic chemoembolization.

Authors:  Timothy W I Clark
Journal:  Semin Intervent Radiol       Date:  2006-06       Impact factor: 1.513

Review 3.  Changes of HBV DNA After Chemoembolization for Hepatocellular Carcinoma and the Efficacy of Antiviral Treatment.

Authors:  Xiao-Jun Lin; Xiang-Ming Lao; Ming Shi; Sheng-Ping Li
Journal:  Dig Dis Sci       Date:  2016-04-22       Impact factor: 3.199

Review 4.  Tumor lysis syndrome and primary hepatic malignancy: case presentation and review of the literature.

Authors:  Sean P Zivin; Youssef Elias; Charles E Ray
Journal:  Semin Intervent Radiol       Date:  2015-03       Impact factor: 1.513

5.  Incidence and risk factors of contrast-induced nephropathy after transcatheter arterial chemoembolization in hepatocellular carcinoma.

Authors:  Mari Aoe; Takafumi Kanemitsu; Takamasa Ohki; Satoru Kishi; Yoshiyasu Ogura; Yuto Takenaka; Toyohiro Hashiba; Hiroko Ambe; Emi Furukawa; Yu Kurata; Masahiro Ichikawa; Ken Ohara; Tomoko Honda; Satoshi Furuse; Katsunori Saito; Nobuo Toda; Naobumi Mise
Journal:  Clin Exp Nephrol       Date:  2019-06-10       Impact factor: 2.801

6.  Acute pancreatitis as a complication of trans-arterial chemoembolization of hepatocellular cancer-case report and review of literature.

Authors:  Padmini Krishnamurthy; Mathew Brown; Sangeeta Agrawal; Robert F Short
Journal:  J Gastrointest Oncol       Date:  2017-02

7.  Risk of acute kidney injury after transarterial chemoembolisation in hepatocellular carcinoma patients: A nationwide population-based cohort study.

Authors:  Bo-Ching Lee; Kao-Lang Liu; Cheng-Li Lin; Chia-Hung Kao
Journal:  Eur Radiol       Date:  2017-06-07       Impact factor: 5.315

8.  The incidence of contrast-induced nephropathy (CIN) following transarterial chemoembolisation (TACE) in patients with hepatocellular carcinoma (HCC).

Authors:  Katsumi Hayakawa; Masato Tanikake; Toshihiko Kirishima; Naomi Yoshinami; Hiroyuki Shintani; Eiji Yamamoto; Taisuke Morimoto
Journal:  Eur Radiol       Date:  2014-02-13       Impact factor: 5.315

Review 9.  Tumor lysis syndrome after transarterial chemoembolization of hepatocellular carcinoma: case reports and literature review.

Authors:  Pei-Min Hsieh; Kao-Chen Hung; Yaw-Sen Chen
Journal:  World J Gastroenterol       Date:  2009-10-07       Impact factor: 5.742

10.  Prognostic factors for acute kidney injury following transarterial chemoembolization in patients with hepatocellular carcinoma.

Authors:  Chunze Zhou; Ruifeng Wang; Yikun Ding; Linan Du; Changlong Hou; Dong Lu; Li Hao; Weifu Lv
Journal:  Int J Clin Exp Pathol       Date:  2014-04-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.